The hypoactive sexual desire disorder treatment market is set to expand at a compounded annual growth rate (CAGR) of 5.2% during the forecast period from 2019 to 2027. Hypoactive sexual desire disorder (HSDD) can be primary, secondary, lifelong, or situational; currently, physicians worldwide are employing either psychotherapy or pharmacotherapy for its treatment.
The recent approval of Bremelanotide (Vyleesi) will propel the HSDD market's growth in the near future. Currently, two drugs, such as Prasterone 6.5 mg vaginal insert and BP101, are under phase 3 clinical trials being investigated for their safety and efficacy in treating HSDD.
Market Synopsis
A multifunctional serotonin agonist and antagonist pharmacodynamic profile increase the popularity of flibanserin for treating HSDD.
Hypoactive sexual desire disorder (HSDD) is the absence of sexual thoughts and fantasies that causes low libido and sex drive in the female population worldwide. The neurochemical basis associated with HSDD is not fully understood, but low sexual desire has been associated with hyperfunction inhibition, hypofunctional excitation, or a combination of both regulated by neuromodulators. Fluctuating sex hormones during the menstrual cycle are also a chief contributing factor to the occurrence of HSDD in the female population worldwide.
The diagnosis of HSDD is challenging, and physicians rely on pharmacotherapy and psychotherapy for its treatment. The PLISSIT model (Permission, Limited Information, Specific Suggestions, and Intensive Therapy) aids in the initial screening of HSDD. Cognitive behavior therapy is offered to patients responding to counseling sessions with a sexual therapist. In pharmacotherapy, antidepressants such as bupropion and buspirone have been used as off-label treatments for HSDD in women showing low sexual drive associated with anxiety and depression.
Testosterone transdermal patches are used as an off-label treatment for premenopausal and postmenopausal women with HSDD. Flibanserin is currently the only drug approved by the USFDA for treating HSDD in premenopausal women by decreasing serotonin activity and increasing norepinephrine and dopamine activity simultaneously.
Increasing stress and fluctuating hormones are responsible for low sexual drive in the female population in the North American region.
North America, with a share of 38.5%, is currently the clear leader in the regional segment of the hypoactive sexual desire disorder (HSDD) treatment market. The chief contributing factors for the growing incidence of low sex drive in the female population in the North American region are increasing stress in daily life and fluctuating hormones associated with the menstrual cycle.
The presence of pharmaceutical companies engaged in drug development for treating HSDD, such as Allergan, Plc., AMAG Pharmaceuticals, S1 Biopharma, Inc., Sprout Pharmaceuticals, Inc., etc., further bolsters market growth in the region. Europe accounts for 32.4% of the market share owing to favorable reimbursement scenarios for drugs prescribed for the treatment of HSDD. Asia Pacific represents a 15.2% market share and is ready to register faster growth during the forecast period, primarily due to the rising incidence of stress in the working women population and developing healthcare infrastructure.
Historical and Forecast Period
This research report presents the analysis of each segment from 2017 to 2027, considering 2018 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2019 to 2027.
Report Scope by Segments
The market is segmented by therapy and by geography.
Pharmaceutical companies providing pharmacotherapy for treating hypoactive sexual desire disorder are AMAG Pharmaceuticals, Allergan, Plc., Ivix, LLX., EndoCeutics, Inc., Emotional Brain BV., S1 Biopharma, Inc., and Sprout Pharmaceuticals, Inc.
Key questions are answered in this report.
What are the strategic collaborations, mergers, and acquisitions taking place in the HSDD treatment market?
Which pharmaceutical companies are providing pharmacotherapy drugs for treating HSDD?
What is the pathophysiology associated with HSDD and the treatment regimen adopted by physicians worldwide?
What are the market size and CAGR of developed regional segments such as North America and Europe in the HSDD treatment market?
Frequently Asked Question:
The market for Hypoactive Sexual Desire Disorder Treatment Market is expected to reach USD$ XX in 2027.
The Hypoactive Sexual Desire Disorder Treatment Market is expected to see significant CAGR growth over the coming years, at 5.2%.
The report is forecasted from 2019 -2027.
The base year of this report is 2018.
Allergan, Plc., AMAG Pharmaceuticals, S1 Biopharma, Inc., Sprout Pharmaceuticals, Inc. are some of the major players in the global market.
